News & Events
Diagnostics firm increases infrastructure to support rising industry demands for design and development of clinical trial assays and companion diagnostics.
Insight Genetics Inc., a molecular diagnostic company dedicated to improving the lives of cancer patients through advanced diagnostics, announced today that it has added six employees to its team, growing its expertise in scientific research and development and quality assurance.
Insight Genetics was on hand at the Drug Information Association’s (DIA) 50th Annual Meeting in San Diego from June 15-19, 2014. Building on efforts to transition academic discoveries into clinical diagnostics, the team presented a poster highlighting processes for implementing Next Generation Sequencing (NGS) assays for the identification of biomarkers driving non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). The poster described an efficient NGS assay validation process for clinical laboratory adoption using practical examples of a targeted DNA-based NSCLC panel and an RNAseq-based assay to stratify subsets of TNBC patients.
Insight Genetics, in collaboration with partners at the British Columbia Cancer Agency, presented a poster at the American Society of Clinical Oncology’s 2014 Annual Meeting in Chicago. The poster highlighted a clinical diagnostic trial in Canada sponsored by Insight Genetics. The trial measures the accuracy of Insight Genetics’ ALK qPCR Assay in identifying oncogenic ALK expression in non-small cell lung cancer (NSCLC).